Revive Announces Completion of Rights Offering for Gross Proceeds of $844,693 to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria

Corporate Breaking News

Home : Revive Announces Completion of Rights Offering for Gross Proceeds of $844,693 to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria

Jun 21 2016	Revive Announces Completion of Rights Offering for Gross Proceeds of $844,693 to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria
TORONTO, ONTARIO--(Marketwired - June 20, 2016) -


Source:http://www.marketwired.com/mw/release.do?id=2135620&sourceType=3

Related News
» Geologix Enhances Management Team and Announces $1,105,000 Unit Offering » PowerVerde, Inc., Enters Into Broad Licensing Agreement Focusing on Waste Heat-to-Power Solutions Using Organic Rankine Cycle and Advanced Steam Technology